MET and non-small cell lung carcinoma: For example, in studies on the mechanism of drug resistance in gefitinib treatment for NSCLC, it was found that the expression of miR-30b was downregulated after treatment with MET inhibitors, and the sensitivity of NSCLC to gefitinib was increased [35,36].